VolitionRx's Nu.Q NETs Assay Selected for French National Sepsis Detection Initiative

VolitionRx Ltd. announced that its Nu.Q NETs H3.1 assay has been selected as the sole biomarker for DETECSEPS, a French government-funded evaluation of early sepsis detection under the France 2030 plan. The program, led by the IHU SEPSIS and supported by a €6.3 million grant, aims to transform emergency care for patients with infection and risk of sepsis progression. This selection represents a significant validation of the biomarker's potential in a national healthcare initiative focused on improving patient outcomes.

Professor Djillali Annane, Scientific Director of DETECSEPS, noted that combining Volition's Nu.Q H3.1 biomarker with a clinical score could improve early identification of sepsis and make a huge difference in emergency settings. He emphasized that H3.1 is highly correlated with disease severity and provides excellent prognostic utility for outcomes such as organ failure and mortality. The biomarker's prognostic power at ICU admission significantly exceeded established severity scores such as APACHE II and SOFA, suggesting it could become a valuable tool for clinical decision-making.

Volition Chief Medical Officer Dr. Andrew Retter highlighted that the company's biomarker can deliver results within one hour on the Immunodiagnostic Systems i10 automated analyzer, potentially enhancing emergency decision-making. This rapid turnaround time is crucial in sepsis cases where early intervention dramatically improves outcomes. Volition believes that through earlier identification of sepsis, lives can be saved, the quality of life of survivors can be improved, and the burden on healthcare systems can be reduced.

The DETECSEPS initiative represents a major step forward in sepsis management, a condition that affects millions globally and has high mortality rates when not detected early. By focusing on early detection through biomarker technology, the program addresses a critical gap in emergency medicine. Volition is providing the Nu.Q H3.1 Assay pro-bono to enable this important evaluation, demonstrating the company's commitment to advancing sepsis care. The selection of a single biomarker for a national program of this scale underscores the potential impact of epigenetic testing in critical care settings.

For further information about Volition's technology and research, visit https://www.Volition.com. The company's participation in DETECSEPS aligns with its broader mission of developing simple, cost-effective blood tests to help detect and monitor life-altering diseases. This initiative could establish a new standard for sepsis detection that combines clinical assessment with objective biomarker data, potentially transforming how emergency departments identify and manage this deadly condition.